{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:32:09Z","timestamp":1766467929829,"version":"3.44.0"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"1112","license":[{"start":{"date-parts":[[2012,3,11]],"date-time":"2012-03-11T00:00:00Z","timestamp":1331424000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>QUESTION  UNDER STUDY: Anticoagulation therapy is routinely used in cases of non ST-segment  elevation acute coronary syndromes (NSTE-ACS). The most commonly used drug in  such events is enoxaparin, a low molecular weight heparin. Fondaparinux, a  synthetic pentasaccharide, is as effective as enoxaparin in terms of survival  or residual angina pectoris and significantly reduces bleeding complications. The  purpose of this study was to assess the magnitude of cost reductions if  enoxaparin were replaced by fondaparinux in Switzerland.\n        METHODS:  Costs of hospital stay for NSTE-ACS with or without bleeding complications at  the Geneva University Hospitals were determined for patients admitted between  July 1st, 2007 and June 30th, 2008. These costs were applied to subjects  recruited in the AMIS Plus registry, which gathers information on ACS in Swiss  hospitals, using three scenarios. Firstly, using the baseline incidence of  bleeding episodes observed in the AMIS plus registry. Secondly, using the  baseline incidence of haemorrhagic episodes observed in the Geneva University  Hospitals sample and thirdly, using the incidence of haemorrhagic episodes  observed in the OASIS-5 study. These results and costs were then extrapolated  to the national level.\n        RESULTS:  At the Swiss national level, replacement of enoxaparin by fondaparinux would  generate annual savings ranging from 854,000 Swiss Francs (scenario 1) to 3,400,000  Swiss Francs (scenario 2) and 2,845,000 Swiss Francs (scenario 3). Estimated  savings accounted for 55 to 63% of total hospital costs.\n        CONCLUSIONS:  Use of fondaparinux instead of enoxaparin in patients with NSTE-ACS could yield  substantial savings at the local as well as the national level in Switzerland.<\/jats:p>","DOI":"10.4414\/smw.2012.13536","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T14:23:21Z","timestamp":1332426201000},"page":"w13536","source":"Crossref","is-referenced-by-count":3,"title":["Fondaparinux  versus enoxaparin in the management of\u00a0acute coronary syndromes in Switzerland"],"prefix":"10.57187","volume":"142","author":[{"given":"Michel\u00a0Pierre","family":"Kossovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre- Fr\u00e9deric","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Gaspoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","published-online":{"date-parts":[[2012,3,11]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1449\/1782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1449\/1783","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1449\/1782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T03:38:55Z","timestamp":1755229135000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/1449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,11]]},"references-count":0,"journal-issue":{"issue":"1112","published-online":{"date-parts":[[2012,3,12]]}},"URL":"https:\/\/doi.org\/10.4414\/smw.2012.13536","relation":{},"ISSN":["1424-3997"],"issn-type":[{"type":"electronic","value":"1424-3997"}],"subject":[],"published":{"date-parts":[[2012,3,11]]}}}